{"name":"Axsome Therapeutics, Inc.","slug":"axsome-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"AXS-02","genericName":"AXS-02","slug":"axs-02","indication":"Neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN)","status":"phase_3"},{"name":"AXS-05","genericName":"AXS-05","slug":"axs-05","indication":"Major depressive disorder (approved)","status":"marketed"},{"name":"AXS-07","genericName":"AXS-07","slug":"axs-07","indication":"Acute migraine with or without aura","status":"phase_3"},{"name":"AXS-07 (meloxicam-rizatriptan)","genericName":"AXS-07 (meloxicam-rizatriptan)","slug":"axs-07-meloxicam-rizatriptan","indication":"Acute migraine with or without aura","status":"phase_3"},{"name":"AXS-12 (Reboxetine)","genericName":"AXS-12 (Reboxetine)","slug":"axs-12-reboxetine","indication":"Major depressive disorder","status":"phase_3"},{"name":"AXS-14 (Esreboxetine)","genericName":"AXS-14 (Esreboxetine)","slug":"axs-14-esreboxetine","indication":"Major depressive disorder","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AXS-02 (oral zoledronate)","genericName":"AXS-02 (oral zoledronate)","slug":"axs-02-oral-zoledronate","indication":"Osteoporosis","status":"phase_3"}]}],"pipeline":[{"name":"AXS-02","genericName":"AXS-02","slug":"axs-02","phase":"phase_3","mechanism":"AXS-02 is a combination of dextromethorphan and quinidine that enhances NMDA receptor antagonism and sigma-1 receptor modulation to reduce neuropathic pain.","indications":["Neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN)","Fibromyalgia"],"catalyst":""},{"name":"AXS-02 (oral zoledronate)","genericName":"AXS-02 (oral zoledronate)","slug":"axs-02-oral-zoledronate","phase":"phase_3","mechanism":"AXS-02 is an oral formulation of zoledronate, a bisphosphonate that inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","indications":["Osteoporosis","Bone metastases and hypercalcemia of malignancy (investigational oral formulation)"],"catalyst":""},{"name":"AXS-05","genericName":"AXS-05","slug":"axs-05","phase":"marketed","mechanism":"AXS-05 is a combination of dextromethorphan and bupropion that enhances serotonergic and noradrenergic neurotransmission while modulating NMDA receptor activity.","indications":["Major depressive disorder (approved)","Treatment-resistant depression (approved)"],"catalyst":""},{"name":"AXS-07","genericName":"AXS-07","slug":"axs-07","phase":"phase_3","mechanism":"AXS-07 is a combination of melitracen (a tricyclic compound) and rizatriptan that works synergistically to treat acute migraine by enhancing serotonergic activity and providing rapid symptom relief.","indications":["Acute migraine with or without aura"],"catalyst":""},{"name":"AXS-07 (meloxicam-rizatriptan)","genericName":"AXS-07 (meloxicam-rizatriptan)","slug":"axs-07-meloxicam-rizatriptan","phase":"phase_3","mechanism":"AXS-07 combines meloxicam (an NSAID) with rizatriptan (a 5-HT1B/1D receptor agonist) to treat acute migraine by reducing inflammation and constricting cranial blood vessels.","indications":["Acute migraine with or without aura"],"catalyst":""},{"name":"AXS-12 (Reboxetine)","genericName":"AXS-12 (Reboxetine)","slug":"axs-12-reboxetine","phase":"phase_3","mechanism":"Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the brain by blocking its reuptake at the presynaptic neuron.","indications":["Major depressive disorder","Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"AXS-14 (Esreboxetine)","genericName":"AXS-14 (Esreboxetine)","slug":"axs-14-esreboxetine","phase":"phase_3","mechanism":"Esreboxetine is a norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the central nervous system by blocking its reuptake at the presynaptic neuron.","indications":["Major depressive disorder","Treatment-resistant depression"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQSTdWbXBIWUpabnhEWUdldmFkYnJuTk5OdjlrcGpyYjljX1c4a19YbGFvelRfSVNfOC1KZXlWcWNySlNINngyMnVxZElqelV3Vlk0RnV0cHBlbVY3RFpSekl2SXdSN3ktT051czNRaGMyVlhpdEw1Nll5NzJqTjBjZGZwX3VhUTZJZTB6QjQzTDhpbmdaWUlhSjNlSmo4dDlDbkRuZUZMcHNCZ2hWT1pxSHQ5QlRXUQ?oc=5","date":"2026-04-01","type":"deal","source":"Benzinga","summary":"Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga","headline":"Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQMlV6SlhmYm5KRURpbWh4TzRzcmJxZHBqUUd4LWJiekJzRXBFUlJ3Ti1BNXA5U3F0clhobHRRc0EwTEdsRzhkSUdBY1hfRVJpTWEyZkdkSWVhU1c2QUk1cmlrVlJvY2hUcXVXNkNQZlpuRzdyS0VENUU1SmowVFZKcDI3U3hCcEFJaWJOUEZhYkJndWF0VGpNVFlzMlZueWtrcW5TNG5lWmJjbUYwZ05BUmpFNWEwZw?oc=5","date":"2026-02-23","type":"earnings","source":"seekingalpha.com","summary":"Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued (AXSM) - seekingalpha.com","headline":"Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued (AXSM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPbTF6R1RzZ05CWlp3Mm83LUJkSjhCOURxVVBhREpjZG5ST1dnRUs1SnJVSWVqekUya01ndFl4a0J2MmVDOTYzOWJFa0tfZWJKYjYxWTdBWFRUTzhlU09JZllWWTF2alNTTXdjeTZDU0MyU1pTXzBrRjhDXzd4TEVsS3NnMDUwRWdaZ1ZxekdybS1HYWVuOGIyNGE0VjFzZDBPeXl0aEFQbEFILUFhQ2JrUkd3?oc=5","date":"2026-02-17","type":"earnings","source":"finviz.com","summary":"Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline - finviz.com","headline":"Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeGNEVUpaMWFhMG9jYy01QWFQejVkRkxNa0Z0Z182QVhfWmFuVmZLcTdnbmZvQWZkVGdrbUltZENxRWtKX0o2R19YdVZkOWkzQXlLbXZpU2NCQUtyWjdGQTZvdmw1aDZRSDVDQTlZN183dVBnWEpFaXRYb01qUmlacV9ya0R0NW5wUUgySUVFRkRDUS1oSnpUNUlGSlMyS09JVDhPaWtRUlhFZGw0bVNWeGZMcElyeWNyUTNEMTNaRXI?oc=5","date":"2026-02-17","type":"earnings","source":"TradingView","summary":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? - TradingView","headline":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQUzJDQTRnQ2pOU0JoUUJRT2YxYm9Qc3hIaFY4WktwR09HeDFLaVRCQ0dRRzF4RHJ1RnN3cTFVUFUyVzVjVFJjZmpuS3VCbTlpQ1RTQi1OcnhPWFZ1ZUJWTHpDN1hwbW51UGlBdUlFU3NrYzdXSWRob1Y0Q3F1QUs3c3dNcl9sNU16amtjT2lB?oc=5","date":"2026-02-05","type":"pipeline","source":"The Motley Fool","summary":"Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool","headline":"Best Biotech Stocks of 2026 and How to Invest in Them","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOZldualVTcmR3dTVxZFhWSnVwdXZfbjl2d2MzWklGYW5GWXJON3hWNVdINzNaVFllZHdjd3QyM1JyRTVnVEZ1NVNtMDRrcndsQ01TLWtnU1pkVXU0bjdJdjNOQU5tUlhfSmdxbmg0MXc1aHVlZ2Rsc1NtVGkxbTFEUzlvVE9XRDFscjJlN19jU2JNM0tzVnZxelNIdEVoUjFCUUhzdFdn?oc=5","date":"2026-01-12","type":"earnings","source":"BioWorld News","summary":"JPM 2026: Year kicks off with biopharma Q4 revenue and guidance - BioWorld News","headline":"JPM 2026: Year kicks off with biopharma Q4 revenue and guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxOUmlYZVBGSEh1TXRUQjA2YkFHNWQ4b1dXN2I2UVJqN2NhWXZWV0phVzNkVGZPU0dNbzIySGJBcVZjODgxaFFDT2luSkpLU2o4S3VqZ1RubFRibGJSeFM5Rlc1RlpMeGcyWUw4V1E5MFVrZThJOWNPVXY5NTJTYWt3dTJ1Y0R6YkMyOUN4c2NpZ1FEaXVxRmdicWNUTXFZMUp5SXFqUWRteWN3R0FRN0hqTU1Mdlh5SHJRTUhFMGZQMlVHV3ZqcVFpNEtraTBsaVhHNFRBNWZoMDVpOGZDMVFXd2pzU2ZxSVFHb2c0RnJWT0cxd0FYbWg0WjFvVXQzNUc1SlE?oc=5","date":"2026-01-05","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), GeneDx Holdings (WGS) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), GeneDx Holdings (WGS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOVTZLNnVJcHV3NVBmNXU0NHVqa1BWNC0xckp0cGxCWUFGSDFnYlV6MjJJTzNpQTQxOWJUZy1TV0V1UlByZDVacF95c0ZLM3hWcXlPay15d3Y4X1lSamE5ZURmM1hzNUZTclQ1RklvU1I4Y1pBTkRFRXFNZ2IwM2M5eUd5WHlvZHRCelN5cXpCN1p5M1hQcnB0Vnd3eU41ZW9ReVE?oc=5","date":"2025-12-31","type":"pipeline","source":"seekingalpha.com","summary":"Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - seekingalpha.com","headline":"Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxObl9IZWx5eU84X1NadWZBT0pSUnJzaVpGSUlwY0VRdnpEWkpiUTlrQnNyNllmOUhnekMxTHowNkQzOVo3ZDRRakxxOThtSGNjM04yanMxWXRCSlVTY211Z3VmOFVEZ3lSQ2ZYZldzWU9BMldKek9fYl9kOUp3QWJIdDZKbjhFT0hMdGkyTWcwZkREcE1rcEI1akV6emZEMm8?oc=5","date":"2025-11-06","type":"pipeline","source":"Yahoo Finance","summary":"Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - Yahoo Finance","headline":"Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOTWd0NUtYTVJXU0VxLU5CMTlWbVNhMWxvalNoSWxJdnFzMXo3bGJSbVE4TGlCVXB3cklKLU84WGlhUDAyeDRyTVdpU3J3cEFhVGdQUkNMU1BnZHhSVl9iT3p6ZnRHTWJLZllkb2c5TzAzdHdtbFY1MkVnVUxhSjMyV194Y3laOGhrWU1ja0dnUVA4WmQyM0d2b1BBdVBDN1hKcHh4ejFTd1phQ3J4N25GSVl2alZtbFNadzlVTU9iVHZITHM?oc=5","date":"2025-11-04","type":"earnings","source":"TradingView","summary":"AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales - TradingView","headline":"AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-06-10","type":"earnings","source":"simplywall.st","summary":"Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - simplywall.st","headline":"Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQUkI3Rzd6WEU5NlZHdEkzR0VBY3pNSkJwdzdKdmpvUjRmU3hGbmlaVGkwQ3NoWGRJSEg3ekg2ZVhNbjMtX3NqRlRBVDI1ZUJHYXpwWkw2SnpXRURaQmhjc2lRanM0WWx2NGVobExGbF9TRjJXci0wNGZrZGFwSmpCZXI1U2V5b3NVQnlWOC1PTFZOUm5fQ000WjJnZzJpbW5DTUNvb05kdUNDU2RJTzM2N29hYlg?oc=5","date":"2025-05-16","type":"regulatory","source":"Reuters","summary":"US FDA approves Amneal's self-administered migraine treatment - Reuters","headline":"US FDA approves Amneal's self-administered migraine treatment","sentiment":"positive"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":6,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}